Core Insights - Aspen Pharmacare aims to secure sub-Saharan African approval for Eli Lilly's weight-loss drug Mounjaro within the year, responding to increasing regional demand for obesity treatments [1][2] - The registration of Mounjaro across sub-Saharan Africa positions Aspen as a significant manufacturing and distribution partner for global drugmakers targeting the untapped GLP-1 weight-loss treatment market [2][3] Market Dynamics - The GLP-1 market in South Africa has reached approximately 2.2 billion rand ($133.64 million) and continues to grow, driven by the launch of Mounjaro [3] - The market value has tripled in 18 months, with Mounjaro's market share increasing from 21% to 52% by the end of January, following regulatory approval for chronic weight management [4] - Sales of Mounjaro are projected to exceed 1.3 billion rand ($78.97 million) for the year ending in June, making it the fastest brand to reach a billion rand in sales within the South African private market [4] Competitive Landscape - In South Africa, Eli Lilly's Mounjaro competes with Novo Nordisk's Wegovy and Ozempic, which are also expanding into the African market following their launch in South Africa [5]

Core Insights - Eli Lilly's Zepbound (tirzepatide) has received FDA approval for a label expansion to include a four-dose single-patient use KwikPen, enhancing patient access and convenience [1][2] - Zepbound is the most prescribed injectable obesity management medication, with patients losing an average of up to 50 pounds, demonstrating strong efficacy [1][2] - The introduction of the KwikPen aims to support patients in their weight management journey, with a self-pay price starting at $299 per month [1][2] Product Details - Zepbound is available in multiple doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, with the 2.5 mg serving as a starting dose [1][2] - The recommended maintenance doses for weight reduction are 5 mg, 10 mg, or 15 mg, administered subcutaneously once per week [1][2] - Zepbound is indicated for adults with obesity or overweight with weight-related medical problems, and it is also FDA-approved for treating moderate-to-severe obstructive sleep apnea [1][2] Clinical Efficacy - In the SURMOUNT-1 trial, participants taking Zepbound 15 mg lost an average of 20.9% of their body weight over 72 weeks, compared to 3.1% with placebo [1][2] - In the SURMOUNT-5 trial, participants on Zepbound experienced an average weight loss of 50 lbs (20.2%), while those on Wegovy lost an average of 33 lbs (13.7%) [1][2] Market Impact - In 2025, over 1 million patients accessed Lilly treatments through LillyDirect, which offers self-pay pricing at a 50% or greater discount compared to other GLP-1 medications [1][2] - One out of every three new patients starting a branded weight management medication was prescribed Zepbound self-pay vials in 2025, indicating strong market demand [1][2] Digital Health Platform - LillyDirect is a digital health platform that connects patients with chronic conditions to necessary care and prescribed medicines, facilitating prescription fulfillment through licensed healthcare providers [2][3]

Core Insights - Eli Lilly has launched a new multi-dose injection pen for its obesity drug Zepbound, named KwikPen, which offers a month's worth of doses in a single device [1][3] - The price for the KwikPen starts at $299 per month for the lowest dose level, available through Lilly's direct-to-consumer platform, LillyDirect [1][3] - The introduction of the KwikPen aims to enhance patient convenience by reducing the number of devices needed for treatment, as it allows patients to take four weekly doses with one pen [2][3] Market Performance - Zepbound has seen significant demand since its market entry in late 2023, contributing to Eli Lilly's majority share in the weight-loss drug market, overtaking rival Novo Nordisk [3][4] - In the fourth quarter, Zepbound generated $4.2 billion in U.S. revenue, marking a 122% increase compared to the previous year [4] - The FDA has approved a label expansion for Zepbound to include the new multi-dose device, indicating regulatory support for the product's growth [4] Strategic Commitment - Eli Lilly emphasizes its commitment to supporting individuals with obesity through innovative treatment options like the Zepbound KwikPen, which is already trusted for other Lilly medications [5]

Financial Data and Key Metrics Changes - In the first quarter of fiscal year 2026, the company generated approximately $261 million in revenue, reflecting a 0.3% decline year-over-year on an as-reported basis, or a 2% decline on an adjusted constant currency basis [14] - GAAP gross profit and margin for the first quarter totaled $161.7 million and 61.9%, compared to $151.7 million and 60% in the prior year period [19] - GAAP net income and earnings per diluted share were $44.1 million and $0.74 during the first quarter, compared to $0 in the prior year period [21] Business Line Data and Key Metrics Changes - Adjusted constant currency pen needle revenue declined approximately 4.4%, while syringe revenue grew by approximately 5.3% and safety product revenue grew approximately 7.3% [17] - Contract manufacturing revenue declined approximately 16.7%, primarily due to the continued insourcing of these products by Becton Dickinson [17] Market Data and Key Metrics Changes - U.S. revenue for the quarter totaled approximately $131 million, reflecting a year-over-year decline of 7.6% on an adjusted constant currency basis, driven by lower pricing and lower volumes [15] - International revenue for the first quarter totaled approximately $130 million, representing an increase of 8.4% on a reported basis and an increase of 4.6% on an adjusted constant currency basis, driven by strength across EMEA and Latin America [16] Company Strategy and Development Direction - The company is focused on transitioning to a broader medical supplies company and drug delivery partner, with a strong emphasis on brand transition and portfolio expansion [6][7] - The company aims to strengthen its core business while selectively expanding its portfolio in areas that leverage existing strengths, particularly in the Medicare Part D channel [9][10] Management's Comments on Operating Environment and Future Outlook - Management expects the recovery in China to be more weighted towards the second half of the fiscal year, given ongoing market dynamics and geopolitical factors [16] - The company reaffirmed its financial guidance for the year, now expecting to be closer to the lower end of the guidance ranges due to incremental U.S. pricing headwinds [18][25] Other Important Information - The company is advancing its GLP-1 strategy, collaborating with over 30 pharmaceutical partners, with initial generic GLP-1 launches anticipated in markets such as Canada, Brazil, China, and India beginning in calendar year 2026 [11][12] - The company generated approximately $17 million in free cash flow during the first quarter and repaid approximately $38 million of outstanding debt, reducing its net leverage level to approximately 2.8 times [23][24] Q&A Session Summary Question: Can you provide insights on U.S. business dynamics, pricing impacts, and the expected recovery in China? - Management noted a year-over-year decline in the U.S. driven by lower pricing and volume, with channel dynamics impacting results. They expect a recovery in China in the second half of the year [30][32] Question: What factors contributed to the strength in international markets? - Management attributed the growth in international markets to superior execution, particularly in Latin America, where a new large customer has driven growth [43] Question: Can you elaborate on the GLP-1 opportunity and the impact of oral therapies? - Management remains confident in the GLP-1 opportunity, noting that injectables have better weight loss profiles and that the market for orals is expanding rather than pulling patients away from injectables [36][38]